Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S-588410 Maintenance in Resected NSCLC
NCT02410369Phase 2Unknown
- Sponsor
- The University of Tokyo
- Start
- Mar 2015
- Primary completion
- Mar 2020
- Modality
- Peptides, Peptide-based Cancer Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of S-588410 in non-small cell lung cancer (NSCLC), sponsored by The University of Tokyo. Status: unknown.
02
Drugs
S-588410
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02410369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02410369.